The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Developments in Glycopeptide Antibiotics
Open accessAbstract
Glycopeptide antibiotics (GPAs) are a key weapon in the fight against drug resistant bacteria, with vancomycin still a mainstream therapy against serious Gram-positive infections more than 50 years after it was first introduced. New, more potent semisynthetic derivatives that have entered the clinic, such as dalbavancin and oritavancin, have superior pharmacokinetic and target engagement profiles that enable successful treatment of vancomycin-resistant infections. In the face of resistance development, with multidrug resistant (MDR) S. pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA) together causing 20-fold more infections than all MDR Gram-negative infections combined, further improvements are desirable to ensure the Gram-positive armamentarium is adequately maintained for future generations. A range of modified glycopeptides has been generated in the past decade via total syntheses, semisynthetic modifications of natural products, or biological engineering. Several of these have undergone extensive characterization with demonstrated in vivo efficacy, good PK/PD profiles, and no reported preclinical toxicity; some may be suitable for formal preclinical development. The natural product monobactam, cephalosporin, and β-lactam antibiotics all spawned multiple generations of commercially and clinically successful semisynthetic derivatives. Similarly, next-generation glycopeptides are now technically well positioned to advance to the clinic, if sufficient funding and market support returns to antibiotic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Performance standards for antimicrobial susceptibility testing
Ferraro, M. J. (2001) · Cited by 9,667
Antibiotic resistance is ancient
D’Costa, V. M., King, C. E., Kalan, L., Morar, M., Sung, W. W. L., Schwarz, C., Froese, D., Zazula, G., Calmels, F., Debruyne, R., et al. (2011) · Nature · doi:10.1038/nature10388 · Cited by 2,720
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Vancomycin-Resistant Enterococci
Cetinkaya, Y., Falk, P., & Mayhall, C. G. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.4.686 · Cited by 1,163
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Mechanisms of vancomycin resistance in Staphylococcus aureus
Gardete, S., & Tomasz, A. (2014) · Journal of Clinical Investigation · doi:10.1172/jci68834 · Cited by 565
Vancomycin resistance in Staphylococcus aureus
Appelbaum, P. C., & Bozdogan, B. (2004) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.03.004 · Cited by 485
Vancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006
Sievert, D. M., Rudrik, J. T., Patel, J. B., McDonald, L. C., Wilkins, M. J., & Hageman, J. C. (2008) · Clinical Infectious Diseases · doi:10.1086/527392 · Cited by 483
Ahmed, M. O., & Baptiste, K. E. (2018) · Microbial Drug Resistance · doi:10.1089/mdr.2017.0147 · Cited by 438
Higgins, D. L., Chang, R., Debabov, D. V., Leung, J., Wu, T., Krause, K. M., Sandvik, E., Hubbard, J. M., Kaniga, K., Schmidt, D. E., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.1127-1134.2005 · Cited by 425
New Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin and Telavancin
Zhanel, G. G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Hoban, D. J., & Karlowsky, J. A. (2010) · Drugs · doi:10.2165/11534440-000000000-00000 · Cited by 352
Antibiotics in the clinical pipeline at the end of 2015
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.72 · Cited by 349
Self-citationEvolution of antibiotic resistance at non-lethal drug concentrations
Andersson, D. I., & Hughes, D. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.03.005 · Cited by 339
A Trivalent System from Vancomycin· d -Ala- d -Ala with Higher Affinity Than Avidin·Biotin
Rao, J., Lahiri, J., Isaacs, L., Weis, R. M., & Whitesides, G. M. (1998) · Science · doi:10.1126/science.280.5364.708 · Cited by 315
Glycopeptide antibiotics: Back to the future
Butler, M. S., Hansford, K. A., Blaskovich, M. A. T., Halai, R., & Cooper, M. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.111 · Cited by 303
Self-citationvan Oosten, M., Schäfer, T., Gazendam, J. A. C., Ohlsen, K., Tsompanidou, E., de Goffau, M. C., Harmsen, H. J. M., Crane, L. M. A., Lim, E., Francis, K. P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3584 · Cited by 289
Optimizing the Clinical Use of Vancomycin
Álvarez, R., López Cortés, L. E., Molina, J., Cisneros, J. M., & Pachón, J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03147-14 · Cited by 258
Imaging peptidoglycan biosynthesis in Bacillus subtilis with fluorescent antibiotics
Tiyanont, K., Doan, T., Lazarus, M. B., Fang, X., Rudner, D. Z., & Walker, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600829103 · Cited by 247
Antibiotics in late clinical development
Fernandes, P., & Martens, E. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.025 · Cited by 247
Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics
Beauregard, D. A., Williams, D. H., Gwynn, M. N., & Knowles, D. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.781 · Cited by 244
Identifying producers of antibacterial compounds by screening for antibiotic resistance
Thaker, M. N., Wang, W., Spanogiannopoulos, P., Waglechner, N., King, A. M., Medina, R., & Wright, G. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2685 · Cited by 211
Glycopeptide antibiotic biosynthesis
Yim, G., Thaker, M. N., Koteva, K., & Wright, G. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.117 · Cited by 202
Okano, A., Isley, N. A., & Boger, D. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704125114 · Cited by 199
Membrane Active Vancomycin Analogues: A Strategy to Combat Bacterial Resistance
Yarlagadda, V., Akkapeddi, P., Manjunath, G. B., & Haldar, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500270w · Cited by 171
Lunde, C. S., Hartouni, S. R., Janc, J. W., Mammen, M., Humphrey, P. P., & Benton, B. M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01710-08 · Cited by 170
Origin, structure, and activity in vitro and in vivo of dalbavancin
Malabarba, A., & Goldstein, B. P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki005 · Cited by 167
Oritavancin: Mechanism of Action
Zhanel, G. G., Schweizer, F., & Karlowsky, J. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir920 · Cited by 167
Hydrophobic Vancomycin Derivatives with Improved ADME Properties: Discovery of Telavancin (TD-6424)
LEADBETTER, M. R., ADAMS, S. M., BAZZINI, B., FATHEREE, P. R., KARR, D. E., KRAUSE, K. M., LAM, B. M. T., LINSELL, M. S., NODWELL, M. B., PACE, J. L., et al. (2004) · The Journal of Antibiotics · doi:10.7164/antibiotics.57.326 · Cited by 165
Total Syntheses of Vancomycin-Related Glycopeptide Antibiotics and Key Analogues
Okano, A., Isley, N. A., & Boger, D. L. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00820 · Cited by 161
In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic
Candiani, G., Abbondi, M., Borgonovi, M., Romanò, G., & Parenti, F. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.2.179 · Cited by 150
Crowley, B. M., & Boger, D. L. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0572912 · Cited by 145
Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria
Blaskovich, M. A. T., Hansford, K. A., Gong, Y., Butler, M. S., Muldoon, C. A., Huang, J. X., Ramu, S., Silva, A. B., Cheng, M., Kavanagh, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02123-w · Cited by 143
Self-citationStructural modifications of glycopeptide antibiotics
Malabarba, A., Nicas, T. I., & Thompson, R. C. (1997) · Medicinal Research Reviews · Cited by 140
Xie, J. H., Pierce, J. G., James, R. C., Okano, A., & Boger, D. L. (2011) · Journal of the American Chemical Society · doi:10.1021/ja207142h · Cited by 140
Xie, J. H., Okano, A., Pierce, J. G., James, R. C., Stamm, S., Crane, C. M., & Boger, D. L. (2011) · Journal of the American Chemical Society · doi:10.1021/ja209937s · Cited by 138
A vancomycin photoprobe identifies the histidine kinase VanSsc as a vancomycin receptor
Koteva, K. K., Hong, H., Wang, X. D., Nazi, I., Hughes, D. W., Naldrett, M. J., Buttner, M. J., & Wright, G. D. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.350 · Cited by 137
Novel Vancomycin Dimers with Activity against Vancomycin-Resistant Enterococci
Sundram, U. N., Griffin, J. H., & Nicas, T. I. (1996) · Journal of the American Chemical Society · doi:10.1021/ja9621298 · Cited by 136
Structure elucidation of the teicoplanin antibiotics
Barna, J. C. J., Williams, D. H., Stone, D. J. M., Leung, T. W., & Doddrell, D. M. (1984) · Journal of the American Chemical Society · doi:10.1021/ja00329a044 · Cited by 136
Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureus
Kim, S. J., Cegelski, L., Stueber, D., Singh, M., Dietrich, E., Tanaka, K. S. E., Parr, T. R., Far, A. R., & Schaefer, J. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.01.031 · Cited by 134
Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria
Hegde, S. S., Reyes, N., Wiens, T., Vanasse, N., Skinner, R., McCullough, J. L., Kaniga, K., Pace, J., Thomas, R., Shaw, J., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.8.3043-3050.2004 · Cited by 134
Nicolaou, K. C., Hughes, R. O., Cho, S. Y., Winssinger, N., Smethurst, C., Labischinski, H., & Endermann, R. (2000) · Angewandte Chemie International Edition · Cited by 132
Nicolaou, K. C., Hughes, R. O., Cho, S. Y., Winssinger, N., Smethurst, C. A., Labischinski, H., & Endermann, R. (2000) · Angewandte Chemie · Cited by 124
Redesign of Glycopeptide Antibiotics: Back to the Future
James, R. C., Pierce, J. G., Okano, A., Xie, J. H., & Boger, D. L. (2012) · ACS Chemical Biology · doi:10.1021/cb300007j · Cited by 118
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
Brade, K. D., Rybak, J. M., & Rybak, M. J. (2016) · Infectious Diseases and Therapy · doi:10.1007/s40121-016-0103-4 · Cited by 108
McMullen, A. R., Anderson, N. W., Wallace, M. A., Shupe, A., & Burnham, C. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01111-17 · Cited by 108
Site-Selective Bromination of Vancomycin
Pathak, T. P., & Miller, S. J. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301566t · Cited by 104
Yarlagadda, V., Sarkar, P., Samaddar, S., & Haldar, J. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601621 · Cited by 102
Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States
Limbago, B. M., Kallen, A. J., Zhu, W., Eggers, P., McDougal, L. K., & Albrecht, V. S. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02187-13 · Cited by 101
Werth, B. J., Jain, R., Hahn, A. W., Cummings, L. A., Weaver, T., Waalkes, A., SenGupta, D. J., Salipante, S. J., Rakita, R. M., & Butler‐Wu, S. M. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.07.028 · Cited by 100
Telavancin: Mechanisms of Action, In Vitro Activity, and Mechanisms of Resistance
Karlowsky, J. A., Nichol, K. A., & Zhanel, G. G. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ534 · Cited by 96
Asymmetric Catalysis at a Distance: Catalytic, Site-Selective Phosphorylation of Teicoplanin
Han, S., & Miller, S. J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja406067v · Cited by 95
Oritavancin: A Long-Half-Life Lipoglycopeptide
Saravolatz, L. D., & Stein, G. E. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ311 · Cited by 93
The Vancomycin−Nisin(1−12) Hybrid Restores Activity against Vancomycin Resistant Enterococci
Arnusch, C. J., Bonvin, A. M. J. J., Verel, A., Jansen, W. T. M., Liskamp, R. M. J., KRUIJFF, B. D., Pieters, R. J., & Breukink, E. J. (2008) · Biochemistry · doi:10.1021/bi801597b · Cited by 92
Glycopeptide Antibiotic To Overcome the Intrinsic Resistance of Gram-Negative Bacteria
Yarlagadda, V., Manjunath, G. B., Sarkar, P., Akkapeddi, P., Krishnamoorthy, P., Shome, B. R., Ravikumar, R., & Haldar, J. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00114 · Cited by 91
Butterfield, J. M., Patel, N., Pai, M. P., ROSANO, T. G., Drusano, G. L., & Lodise, T. P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01674-10 · Cited by 88
Binding of glycopeptide antibiotics to a model of a vancomycin-resistant bacterium
Cooper, M. A., & Williams, D. H. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(00)80008-3 · Cited by 85
Self-citationVancomycin and Oritavancin Have Different Modes of Action in Enterococcus faecium
Patti, G. J., Kim, S. J., Yu, T., Dietrich, E., Tanaka, K. S. E., Parr, T. R., Far, A. R., & Schaefer, J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.06.064 · Cited by 82
Okano, A., Nakayama, A., Schammel, A. W., & Boger, D. L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja507009a · Cited by 82
Chemical Tailoring of Teicoplanin with Site-Selective Reactions
Pathak, T. P., & Miller, S. J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4038998 · Cited by 77
Multivalent Drug Design. Synthesis and In Vitro Analysis of an Array of Vancomycin Dimers
Griffin, J. H., Linsell, M. S., Nodwell, M. B., Chen, Q., Pace, J., Quast, K. L., Krause, K. M., Farrington, L., Wu, T. X., Higgins, D. L., et al. (2003) · Journal of the American Chemical Society · doi:10.1021/ja021273s · Cited by 77
Yarlagadda, V., Samaddar, S., Krishnamoorthy, P., Shome, B. R., & Haldar, J. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201507567 · Cited by 77
Okano, A., James, R. C., Pierce, J. G., Xie, J. H., & Boger, D. L. (2012) · Journal of the American Chemical Society · doi:10.1021/ja302808p · Cited by 76
Lawson, M. C., Shoemaker, R. L., Hoth, K. B., Bowman, C. N., & Anseth, K. S. (2009) · Biomacromolecules · doi:10.1021/bm900410a · Cited by 70
Tackling vancomycin-resistant bacteria with ‘lipophilic–vancomycin–carbohydrate conjugates’
Yarlagadda, V., Konai, M. M., Manjunath, G. B., Ghosh, C., & Haldar, J. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.144 · Cited by 70
Okano, A., Nakayama, A., Wu, K., Lindsey, E. A., Schammel, A. W., Feng, Y., Collins, K. C., & Boger, D. L. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b01008 · Cited by 69
Johnson, J. A., Feeney, E. R., Kubiak, D. W., & Corey, G. R. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv156 · Cited by 68
Dalbavancin for the treatment of acute bacterial skin and skin structure infections
Ramdeen, S. K., & Boucher, H. W. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1075508 · Cited by 65
Yoganathan, S., & Miller, S. J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501872s · Cited by 65
Guan, D., Chen, F., Xiong, L., Tang, F., Faridoon, Qiu, Y., Zhang, N., Gong, L., Li, J., Lan, L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01345 · Cited by 62
Ambrose, P. G., Drusano, G. L., & Craig, W. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis001 · Cited by 61
Ghosh, M., & Miller, M. J. (1996) · Bioorganic & Medicinal Chemistry · doi:10.1016/0968-0896(95)00161-1 · Cited by 60
Silverman, S. M., Moses, J. E., & Sharpless, K. B. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604765 · Cited by 58
Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram‐Positive Infections
Roberts, K. D., Sulaiman, R., & Rybak, M. J. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1641 · Cited by 55
TD-1792 versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections
Stryjewski, M. E., Potgieter, P. D., Li, Y., Barriere, S. L., Churukian, A., Kingsley, J., Corey, G. R., & for the TD-1792 Investigators Group (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00712-12 · Cited by 55
Synthesis of Tridecaptin–Antibiotic Conjugates with in Vivo Activity against Gram-Negative Bacteria
Cochrane, S. A., Li, X., He, S., Yu, M., Wu, M., & Vederas, J. C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01578 · Cited by 54
Kavanagh, K. T., Abusalem, S., & Cormier, L. E. (2017) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-017-0193-0 · Cited by 52
Antibiotic resistance–mediated isolation of scaffold-specific natural product producers
Thaker, M., Waglechner, N., & Wright, G. D. (2014) · Nature Protocols · doi:10.1038/nprot.2014.093 · Cited by 49
Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin
Steele, J. M., Seabury, R. W., Hale, C. M., & Mogle, B. T. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12580 · Cited by 48
Review of dalbavancin, a novel semisynthetic lipoglycopeptide
Kim, A., Kuti, J. L., & Nicolau, D. P. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.5.717 · Cited by 47
From Vancomycin to Oritavancin: The Discovery and Development of a Novel Lipoglycopeptide Antibiotic
Allen, N. E. (2010) · Anti-Infective Agents · doi:10.2174/187152110790886745 · Cited by 47
Leuthner, K. D., Buechler, K., Kogan, D., Saguros, A., & Lee, S. P. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s86330 · Cited by 47
Treatment of gram - positive infections in critically ill patients
Guillamet, C. V., & Kollef, M. H. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-92 · Cited by 45
Boonyarattanakalin, S., Hu, J., Dykstra, S. A., August, A., & Peterson, B. R. (2006) · Journal of the American Chemical Society · doi:10.1021/ja067674f · Cited by 41
Hill, C. M., Krause, K. M., Lewis, S. R., Blais, J., Benton, B. M., Mammen, M., Humphrey, P. P. A., Kinana, A. D., & Janc, J. W. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01737-09 · Cited by 41
Pinchman, J. R., & Boger, D. L. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4004494 · Cited by 38
Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin
Cheng, M., Ziora, Z. M., Hansford, K. A., Blaskovich, M. A. T., Butler, M. S., & Cooper, M. A. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob42428f · Cited by 34
Self-citationTsuji, B. T., Leonard, S. N., Rhomberg, P. R., et al. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.11.011 · Cited by 33
Brieke, C., Kratzig, V., Haslinger, K., Winkler, A., & Cryle, M. J. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02452d · Cited by 33
How To Make a Glycopeptide: A Synthetic Biology Approach To Expand Antibiotic Chemical Diversity
Yim, G., Wang, W., Thaker, M., Tan, S., & Wright, G. D. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00105 · Cited by 33
Chen, S., Wu, Q., Shen, Q., & Wang, H. (2015) · ChemBioChem · doi:10.1002/cbic.201500542 · Cited by 31
New Antimicrobial and Biocompatible Implant Coating with Synergic Silver–Vancomycin Conjugate Action
Varisco, M., Khanna, N., Brunetto, P. S., & Fromm, K. M. (2014) · ChemMedChem · doi:10.1002/cmdc.201400072 · Cited by 31
Park, O., Choi, H., Kim, G., & Kim, W. (2016) · ChemBioChem · doi:10.1002/cbic.201600241 · Cited by 29
Synthesis of rigidly-linked vancomycin dimers and their in vivo efficacy against resistant bacteria
Lu, J., Yoshida, O., Hayashi, S., & Arimoto, H. (2006) · Chemical Communications · doi:10.1039/b613319c · Cited by 28
Leuthner, K. D., Vidaillac, C., Cheung, C. M., & Rybak, M. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00452-10 · Cited by 27
Investigation into the functional impact of the vancomycin C-ring aryl chloride
Pinchman, J. R., & Boger, D. L. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.06.080 · Cited by 26
Lepak, A. J., Zhao, M., & Andes, D. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00281-17 · Cited by 26
Szűcs, Z., Csávás, M., Rőth, E., Borbás, A., Batta, G., Perret, F., Ostorházi, E., Szatmári, R. Z., Vanderlinden, E., Naesens, L. M. J., et al. (2016) · The Journal of Antibiotics · doi:10.1038/ja.2016.80 · Cited by 22
Assessment of Oritavancin Serum Protein Binding across Species
Arhin, F. F., Belley, A. C., McKay, G. A., Beaulieu, S., Sarmiento, I., Parr, T. R., & Moeck, G. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00271-10 · Cited by 20
Yarlagadda, V., Samaddar, S., & Haldar, J. (2016) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2015.12.007 · Cited by 18
Zhang, S., Yang, Q., Xu, L., Chang, J., & Sun, X. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.039 · Cited by 15
Belley, A. C., Arhin, F. F., & Moeck, G. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01873-17 · Cited by 14
A stepwise dechlorination/cross-coupling strategy to diversify the vancomycin ‘in-chloride’
Wadzinski, T. J., Gea, K. D., & Miller, S. J. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.12.027 · Cited by 11
(2017) · PubMed Central
Cited by
Gan, B. H., Gaynord, J., Rowe, S. M., Deingruber, T., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00729c · Cited by 511
Molecular mechanisms of vancomycin resistance
Stogios, P. J., & Savchenko, A. (2020) · Protein Science · doi:10.1002/pro.3819 · Cited by 381
Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections
Ma, Y., Wang, C., Li, Y., Li, J., Wan, Q., Chen, J., Tay, F. R., & Niu, L. (2020) · Advanced Science · doi:10.1002/advs.201901872 · Cited by 314
Metadata
- Authors
- Blaskovich, M. A. T., Hansford, K. A., Butler, M. S., Jia, Z., Mark, A. E., & Cooper, M. A.
- Venue
- ACS Infectious Diseases
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-01-24
- Volume
- 4
- Issue
- 5
- Pages
- 715-735
- ISSN
- 2373-8227 (ISSN-L)
- OpenAlex
- W2785104789
- Cited by
- 265
- References
- 105
- FWCI
- 18.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.